Background: Three acid-reducing operations have recently been described for the laparoscopic treatment of peptic ulcer disease. These consist of a posterior truncal vagotomy combined with either (1) an anterior seromyotomy (SERO), (2) an anterior highly selective vagotomy (AHSV), or (3) a linear stapled lesser curvature excision (STAP). The purpose of this study was to investigate the physiologic effects of these procedures in terms of basal and maximal acid outputs.
Methods: Fifty New Zealand rabbits were prospectively randomized into five open laparotomy groups (n = 10): a control group without vagal manipulation (CON), a bilateral truncal vagotomy with pyloromyotomy group (VP), a SERO group, an AHSV group, and a STAP group. All animals underwent placement of a gastrostomy tube for subsequent gastric secretory analysis. On postoperative day 6, basal acid outputs (BAO) and maximal acid outputs (MAO) following IV pentagastrin stimulation (30 microg/kg/h) were measured. Results were compared statistically using the ANOVA method.
Results: Pentagastrin stimulation was associated with a significant increase in MAO in the CON group (p < 0.05 vs BAO); however, this response was effectively blunted in all the experimental groups. There were no differences in BAO or MAO between any of the vagotomized groups (SERO, HSV, STAP, VP).
Conclusions: We conclude that the three acid-reducing procedures modified for laparoscopy are equally efficacious in reducing gastric acid secretion and that they compare favorably with VP. To our knowledge, this is the first report comparing basal and stimulated gastric acid secretion between these new acid-reducing techniques.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s004649900312 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prevalence of Gastroesophageal Reflux in Interstitial Lung Diseases Clinic.
Cureus
December 2024
Pulmonology, Jinnah Postgraduate Medical Centre, Karachi, PAK.
Background Interstitial lung diseases (ILDs) are a group of non-infectious diseases characterized by interstitial inflammation and fibrosis on histological examination. Gastroesophageal reflux disease (GERD) is common in this patient population, but whether there is a causal or coincidental relationship is not yet clear. It still remains unsettled how to diagnose GERD, and the role of different treatment modalities for GERD, in these lung disorders.
View Article and Find Full Text PDFRelative Bioavailability of Dordaviprone (ONC201) is Not Affected by Co-Administration of the Proton-Pump Inhibitor Rabeprazole.
J Clin Pharmacol
November 2024
Chimerix Inc., Durham, NC, USA.
Dordaviprone (ONC201) is a novel, orally administered, anti-cancer, small molecule imipridone with demonstrated antitumor effects in patients with glioma. Dordaviprone in vitro solubility is significantly reduced at pH >4.5.
View Article and Find Full Text PDFIntegrated Population Pharmacokinetics of Daprodustat in Patients with Chronic Kidney Disease with Anemia.
Clin Pharmacokinet
September 2024
Leiden Experts on Advanced Pharmacokinetics and Pharmacodynamics (LAP&P), Leiden, The Netherlands.
Article Synopsis
- - Daprodustat, a new treatment for anemia in chronic kidney disease (CKD) patients, was analyzed to understand how various factors affect its pharmacokinetics in adults, focusing on its absorption, distribution, metabolism, and excretion in dialysis and non-dialysis patients.
- - The study involved data from multiple clinical trials with 707 participants, examining how body weight and the use of certain medications (like clopidogrel) influenced daprodustat's clearance and absorption.
- - Results indicated that daprodustat followed a three-compartment distribution model with specific influences from body weight and dialysis status, while other factors did not significantly impact the drug's effectiveness.
Population Pharmacokinetics of Capivasertib in Patients with Advanced or Metastatic Solid Tumours.
Clin Pharmacokinet
August 2024
Clinical Pharmacology and Quantitative Pharmacology, BioPharmaceuticals R&D, AstraZeneca, Boston, MA, USA.
Article Synopsis
- Capivasertib is a selective pan-AKT inhibitor being studied for its pharmacokinetics, which refers to how the drug is absorbed, distributed, metabolized, and excreted in the body, particularly in cancer patients.
- The study analyzed data from phase I and II trials involving 441 patients, testing various dosing schedules and combinations to evaluate the drug's performance and how different factors like age, weight, and concurrent medications affect its effectiveness.
- A three-compartment model was identified to describe capivasertib's pharmacokinetics, showing that it has a moderate clearance rate that decreases over time, with steady-state drug levels expected after a few days of dosing.
Exudate Unidirectional Pump to Promote Glucose Catabolism Triggering Fenton-Like Reaction for Chronic Diabetic Wounds Therapy.
Adv Sci (Weinh)
October 2024
College of Polymer Science and Engineering, State Key Laboratory of Polymer Materials Engineering, Sichuan University, Chengdu, 610054, China.
The massive accumulation of exudate containing high concentrations of glucose causes wound infection and triggers the release of inflammatory factors, which in turn delays the closure of diabetic wounds. In this study, a Janus membrane is constructed by combining glucose oxidase (GOx) and copper ions (Cu) for the treatment of diabetic wounds, which is named as Janus@GOx/Cu. It consists of hydrophobic, transitional, and superhydrophilic layers in a three-layer structure with gradient hydrophilicity for self-pumping properties.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!